SCHEMBL21415430

SCHEMBL21415430

CC(=O)N[C@H]1C(CCCCO)O[C@H](CO)[C@H](O)[C@@H]1O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ THRB P10828 1/20 0.50
▸ CD69 Q07108 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ LGALS8 O00214 1/20 0.41
▸ LGALS3 P17931 1/20 0.41
▸ LGALS4 P56470 1/20 0.41
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ PYGB P11216 2/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24768349 0.89 ALDH1A1 (0.53) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL3295284 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL3296000 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL6944012 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL23478019 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL21947408 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL3295282 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL6942761 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL3295994 0.89 MAPK1 (0.65) MAPK1ALDH1A1THRBCD69SMN1; SMN2
SCHEMBL23848966 0.88 MAPK1 (0.61) MAPK1ALDH1A1THRBCD69SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3608406-B1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS INC (US) 2023-02-15 — — EP disclosed
EP-3137091-B1 CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION IONIS PHARMACEUTICALS INC (US) 2020-12-02 — — EP disclosed
EP-3690049-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION Ionis Pharmaceuticals, Inc. (US) 2020-08-05 — — EP disclosed
EP-3546579-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE Ionis Pharmaceuticals, Inc. (US) 2019-10-02 — — EP disclosed
Send feedback